Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial
- D Thaçi
- , A M Soliman
- , K Eyerich
- , A Pinter
- , M Sebastian
- , K Unnebrink
- , S Rubant
- , D A Williams
- , P Weisenseel
- AbbVie Inc.
- North Chicago
- Department of Dermatology and Allergy
- Technical University of Munich
- Johann Wolfgang Goethe-University
- Gemeinschaftspraxis für Dermatologie
- Mahlow
- GlaxoSmithKline Germany
- AbbVie Deutschland GmbH & Co. KG
- Augenklinik des Klinikums Ludwigshafen
- Dermatologikum Hamburg and SCIderm Research Institute
- AMEDON GmbH Lübeck
22
Link opens in a new tab
Citations
(Scopus)